Cytokinetics Q4 2024 GAAP EPS $(1.26) Misses $(1.17) Estimate, Sales $16.927M Beat $1.742M Estimate

Benzinga
02-28

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.17) by 7.69 percent. This is a 8.7 percent increase over losses of $(1.38) per share from the same period last year. The company reported quarterly sales of $16.927 million which beat the analyst consensus estimate of $1.742 million by 871.94 percent. This is a 912.38 percent increase over sales of $1.672 million the same period last year.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10